Featured Content

Lung Cancer: How to Treat Patients Without an Actionable Mutation

Chapter 2: Dr. Levy discusses the treatment of patients in whom there are no targetable mutations.

Is Indication-specific Pricing for Cancer Drugs on the Horizon?

At War on Cancer, numerous figures in cancer care discussed innovations to reduce the costs associated with drugs.

Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC

Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it's unclear the role it will have in the first-line.

Ghost and Honorary Authorship in Cancer Research

Despite stigma and efforts to limit prevalence, ghost and honorary authorship remain widespread in clinical trials.

Q&A With Dana Carroll, PhD, Highlights CRISPR's Growing Role in Genome Editing

In this question-and-answer session, CTA asked Dr Carroll about CRISPR-Cas9, the state of the science of genome editing, and its implications for oncology.

Featured Slideshow

Targeted Therapy for Patients With Lung Cancer

Factors that affect survival, genetic mutations, and more.

Lung Cancer Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters